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analytical sample contained 26,349 admissions: 762 stays
involved mechanical ventilation, 9495 had ICU time, and 16,092
had neither. Hospital mortality rates were 27.7%, 23.8% and
7.6% for these three groups, respectively. Median cost per stay
was substantially higher for those with ventilation ($39,493)
versus those with ICU time but no ventilation ($25,798) and
those with neither ($7261). Average length of stay in the ICU
was 14 days and 9 days for those with and without ventilation,
respectively. Average anti-infective drug costs were 1.79 times
higher in the ventilator group compared with the ICU group.
CONCLUSION: VAP is an area of high unmet need. Among
these 1500 hospitals, 2003 costs for those with mechanical ven-
tilation were 1.5 times higher than a group of NP cases that were
fairly complex, as indicated by some receipt of intensive care 
services.
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OBJECTIVE: To estimate lifetime medical cost of chronic hepati-
tis B in the United States from the societal perspective.
METHODS: A hypothetical 35-year old cohort of 100,000 indi-
viduals with chronic hepatitis B was tracked in a Markov model
of the natural history of disease. The model assumed standard
clinical care for disease complications, but did not include antivi-
ral treatment. Disease outcomes modeled included cirrhosis,
hepatocellular carcinoma, liver transplantation and death.
Annual transition parameters were estimated from long-term
disease progression data in the literature. Outcome speciﬁc cost
data were derived from published studies and the MarketScan®
database. Expected lifetime medical cost was determined as the
sum of weighted average medical cost of health outcomes over
the cohort lifetime discounted at 3% annual rate and adjusted
to 2005 U.S. dollars. Impact of variations in model parameters
was assessed in one-way sensitivity analyses. RESULTS: The
expected per patient lifetime medical cost of chronic hepatitis B
for the 35-year old cohort was $34,760 (range in sensitivity
analyses: $9367−$59,298). About 73% of the cost was for cir-
rhosis, 10% for hepatocellular carcinoma and 11% for liver
transplantation. The cost varied with the initial age at infection
of the cohort: for a cohort aged 25 years at infection, the cost
was 11% more than the cost for the 35-year olds, and for a 
45-year old cohort, the cost was 16% less than the cost for the
35-year olds. The cost estimate was most sensitive to the annual
rate of developing compensated cirrhosis. CONCLUSIONS:
Life-time medical cost of a chronic hepatitis B patient is sub-
stantial. Identiﬁcation of the disease at early stage for anti-
viral treatment could reduce the likelihood of developing end-
stage liver diseases and avert higher costs.
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OBJECTIVE: To evaluate the economic implications of upper
respiratory tract infection to the Nigerian society. METHODS:
It involves Cost of Illness analysis among upper respiratory tract
infection Out- Patients in Lagos University Teaching Hospital.
Data collected from 182 case notes include; demographics, diag-
nosis, diagnostic tests, no of visits, and prescribed drugs. Direct
and indirect costs were included. The costs include, personnel,
diagnostic tests, transport and antibacterial cost. The hospital
cost of drugs and tests were used. Stop-watch time studies and
monthly earnings were used to calculate the personnel costs.
Average time spent at each visit and expected earnings were used
to calculate the indirect costs. The current hospital costs were
used for all calculations hence neither discounting nor inﬂation
was considered. RESULTS: Total cost of drugs = N358,790.00
($2462.80); Average = N1971.40 ($14.10) Personnel cost =
N49,156.40 ($351.12); Average = N270.00 ($1.93) Diagnostic
Test cost = N9100.00 ($65.00); Average = N50.00 ($0.36) Trans-
port cost = N36,930.00 ($263.80); Average = N202.91 ($1.45)
Indirect cost = N103,350.00 ($738.21) Average = N567.86
($4.06) Cost of illness = N557,326.40 ($3981.10) Average =
N3062.23 ($21.87). Cost of drugs for each disease condition
Acute Otitis media (n = 45 = N24, 526.00 ($175.20); Average =
N545.02 ($3.90). Chronic Superative Otitis media (n = 37) = N
42,982.00 ($307.01); Average = N1161.68 ($8.30) onchopneu-
monia (n = 70) = N257, 299.00 ($1837.85); Average = N
3675.41 ($26.25) Tonsilitis (n = 12) = N14, 923.00 ($106.60);
Average = N1243.58 ($8.90). Other) = N19060.00 ($136.14);
Average = N1058.94 ($7.56). Prevalence of Otitis media in
Nigeria = 29.0% in children below 5 years. = 7,772,000 cases
(7.7million cases) Average cost of Otitis media = N823.27
($5.88) Cost of drugs for 7.7 million cases of otitis media alone
= N6, 398,454,440.00 (Over N6.3 billion) (>$450million).
CONCLUSION: Cost of therapy associated with URTI is enor-
mous. This high cost might be partly due to the use of antibi-
otics in most cases of URTI, a good proportion of which are
viral. The use of treatment guidelines is necessary to ensure a
wise use of the limited resources.
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OBJECTIVES: To estimate direct medical costs associated to
adult patients with HIV/AIDS in second and third level hospitals
in the Social Security Mexican Institute. METHODS: Partial eco-
nomic evaluation was performed employing a one-year survey to
identify patients with HIV/AIDS resource use. The study revised
hospital records in 8 second level hospitals and 2 third level hos-
pitals in Mexico City throughout 2003. Resource use estimates
include outpatient and inpatients services (visits to physicians or
specialists, laboratory and gabinet exams, medications, emer-
gency services, hospitalization, etc.). The research estimates total
direct medical costs and average costs per patient per year. The
analysis was conducted from the healthcare payer’s perspective.
All costs were expressed in 2005 US$. RESULTS: A total of 1969
adult patients with HIV/AIDS were recruited with an average age
of 39 ± 10 years; 86.4% were male. The evolution average time
with HIV was of 6 ± 3 years. 29% of patients were in clinical
stage A; 26% in clinical stage B and 45% in clinical stage C. The
total direct medical cost of these patients on a 1-year follow up
was US$1.107.952,58. Eighty-eight percent of this amount cor-
responds to antiretroviral drugs, 10% to physician’s or special-
ists visits and 2% to non-antiretroviral drugs and laboratory
exams. A total of 9.6% of the sample required inpatient services
with a mean cost per patient of US$ 3103.2. Outpatient services
had an annual mean cost per patient of US$ 5665.1 and the
annual expected cost per patient in the Social Security Mexican
Institute was estimated in US$ 5964.6. CONCLUSIONS: Eco-
nomic consequences of HIV/AIDS patients are substantial for the
Mexican Health Budget, especially due to antiretroviral drugs.
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A joint effort among decision-makers, physicians, society, phar-
maceutical industry, and the Mexican scientiﬁc community in
general would be useful for reducing the high costs of these 
diseases.
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OBJECTIVES: To model the expected rate of clinical failure of
initial empiric therapy and economic burden likely to be associ-
ated with the presence of MRSA in patients hospitalized with
cSSSI in the United States. METHODS: Using published data on
1) the prevalence of MRSA and other bacterial pathogens in
cSSSI; 2) the in vitro susceptibility rates of 5 commonly used
antibiotic regimens in cSSSI in relation to the most pervasive
pathogens identiﬁed above; and 3) estimated costs of failure of
initial, empiric treatment of cSSSI from a recent study of a large
US multi-hospital database, we developed a model to simulate
the expected clinical and economic impact of MRSA. RESULTS:
At a base case assumption of a 55% prevalence of Staphylococ-
cus aureus pathogens in cSSSI, half of them being methicillin-
resistant (MRSA = 27.5%), the model projected a clinical failure
rate of 35.9% and weighted mean inpatient treatment costs of
$5492. At an alternative assumption of zero prevalence of
MRSA, the model projected a clinical failure rate of 18.4% and
a weighted mean cost of $4869, yielding $623 ($5492 less
$4869) as the incremental cost of methicillin resistance to the
average patient hospitalized with cSSSI. This translated into an
expected health care burden of approximately $500 million for
the 800,000 patients hospitalized for cSSSI annually. Raising the
market share of antibiotics with in vitro activity against MRSA
from the current 20% to 50% would reduce the expected eco-
nomic burden by $200 million; raising it to 100% would elim-
inate the burden altogether. CONCLUSIONS: Our model
simulated the expected clinical failure rates and economic impact
of use of initial empiric regimens for cSSSI with varying levels of
coverage—as represented by in vitro activity—for MRSA, and
how this expected economic impact may be offset with suitable
change in mix of initial, empiric antibiotic therapy.
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OBJECTIVES: Identify new CDAD cases, readmission rate and
estimate cost over one year. METHODS: All CDAD cases were
identiﬁed in Massachusetts discharge data using ICD-9-CM
codes and patient identiﬁers. Index stays occurred from October
31, 2001–September 30, 2002. The new case cohort excluded
patients with CDAD-related admissions in the previous year. For
primary CDAD cases (principal diagnosis: CDAD), all stay costs
(accommodations and ancillaries) were deemed related. For sec-
ondary CDAD cases, APR-DRG assignment, severity and length
of stay (LOS) were used to calculate the incremental care costs
due to CDAD. All charges were adjusted (cost-to-charge, inﬂa-
tion, geography) to reﬂect national costs (2005 US$). RESULTS:
The 4015 new cases of CDAD identiﬁed reﬂect a prevalence of
1% among hospitalized patients. Almost all (93%) hospitals
treated 1 case (range: 1–312). Of 1310 primary CDAD cases,
66% were female, with mean age of 72 years (±17.2), mean LOS
of 6.9 days (median: 5) and mean cost of $10,260 (median:
$5752) per stay. Secondary CDAD (2705 cases) was similar
demographically but led to longer stays (mean: 15.7, median: 11
days); suffered higher (p < 0.001) inpatient case fatality rates
(13% vs. 5%); and were more expensive than primary cases
(mean: $32,352, median: $16,842). For secondary cases, CDAD-
related costs comprised 40% ($12,999) of total mean cost. Over
one year, 18% of index stay survivors were readmitted for
CDAD, within 51 days on average (mean 1.3 readmissions per
patient, range: 1–6). Total one-year inpatient cost for CDAD
management was estimated at $56 million. CONCLUSIONS:
CDAD has both clinical and economic consequences. It is wide-
spread in hospitals, generates substantial care costs for those
admitted for CDAD management, and increases inpatient costs
dramatically when it occurs as a complication. Recurrent CDAD
leads to re-hospitalization, typically within two months, further
increasing the cost burden of CDAD.
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OBJECTIVES: Although the prevalence of hepatitis C virus
(HCV) infections is higher among the United States veterans than
in the general population, a paucity of pharmacoeconomic
research has been conducted from its perspective. This study
compared the cost-utility of the current peginterferon regimens
from the perspective of the Veterans Affairs (VA) health care
system. METHODS: A Markov model for treatment-naïve
chronic hepatitis C patients was developed to evaluate 1) pegin-
terferon alfa-2a plus ribavirin (PEG 2a + R); 2) peginterferon
alfa-2b plus ribavirin (PEG 2b + R); and 3) no therapy. Patient
cohorts were 45 or 55 year-old males with liver ﬁbrosis and
without cirrhosis. Data for the model were obtained from clini-
cal trials and published literature. All costs were based on VA
costs and reﬂect 2005 U.S. dollars. The lifetime expected costs,
quality-adjusted life years (QALYs) gained, and incremental net
monetary beneﬁt (INMB) with HCV treatments were deter-
mined. Ninety-ﬁve percent conﬁdence intervals (CI) were gener-
ated from the Monte Carlo simulations. RESULTS: Both
peginterferon regimens were signiﬁcantly more cost-effective
than no treatment, though no differences in costs or QALYs were
noted between the two peginterferon regimens. For 45 year-old
cohort with a genotype 1 infection, the INMB was $128,583
(95% CI $79,279 to $177,308) and $128,025 (95% CI $80,425
to $173,448) versus no treatment for PEG 2a + R and PEG 2b
+ R, respectively. Treatment with either peginterferon regimen
produced signiﬁcantly lower lifetime HCV-related medical costs
for genotype 2 or 3 infections, but not genotype 1. CONCLU-
SIONS: PEG 2a + R and PEG 2b + R were found to be similar
cost-effective treatments for patients with HCV infections, par-
ticularly with genotypes 2 and 3. However, no signiﬁcant differ-
ences in costs or efﬁcacy were observed between these treatment
regimens.
